Cambridge Investment Research Advisors, Inc. Intellia Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 19,726 shares of NTLA stock, worth $258,607. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,726
Previous 13,004
51.69%
Holding current value
$258,607
Previous $152,000
7.89%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding NTLA
# of Institutions
336Shares Held
98.3MCall Options Held
784KPut Options Held
713K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$171 Million1.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$141 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$126 Million0.0% of portfolio
-
State Street Corp Boston, MA4.51MShares$59.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.8MShares$49.8 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $997M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...